The Journal of dermatological treatment最新文献

Oral roflumilast for psoriasis: a real-world 24-week prospective cohort study.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-11 DOI: 10.1080/09546634.2025.2464107

Ana Maria Lé, Orhan Yilmaz, Martim Luz, Tiago Torres

{"title":"Oral roflumilast for psoriasis: a real-world 24-week prospective cohort study.","authors":"Ana Maria Lé, Orhan Yilmaz, Martim Luz, Tiago Torres","doi":"10.1080/09546634.2025.2464107","DOIUrl":"https://doi.org/10.1080/09546634.2025.2464107","url":null,"abstract":"Objective: Psoriasis is a chronic inflammatory skin disease with significant physical and psychological burden, often associated with comorbidities such as obesity and cardiovascular disease. Current treatments include conventional systemic therapies and targeted biologic and non-biologic therapies, with several limitations related to safety, efficacy, and cost. Roflumilast, a selective PDE4 inhibitor, shows potential as an oral therapy for psoriasis due to its anti-inflammatory effects and favorable safety profile. This study aimed to evaluate the real-world effectiveness and safety of oral roflumilast in moderate-to-severe plaque psoriasis.Methods: Prospective cohort study at a single center in Portugal including adults with moderate-to-severe psoriasis treated with oral roflumilast 500 mcg once daily.Results: Among fifty-eight patients (baseline median PASI 13.7 ± 5.5), 63.0% achieved PASI < 5, 47.8% PASI < 3, and 21.7% PASI < 1 by week 24 (mNRI). Weight loss occurred in 53.4%, with a mean reduction of 6 kg ± 4.3. Mild gastrointestinal symptoms were common but rarely caused discontinuation. No serious adverse events were reported.Conclusion: Roflumilast demonstrated real-world effectiveness and a favorable safety profile in moderate-to-severe plaque psoriasis. Additional benefits, including weight loss and no need for laboratory monitoring, make it a promising treatment option, particularly for patients with comorbidities or limited access to biologic therapies.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2464107"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expanding the therapeutic horizons of spesolimab: a review of off-label applications for inflammatory skin diseases.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-16 DOI: 10.1080/09546634.2025.2460582

Hanlin Zhang, Jia Zhou, Keyun Tang, Xinyi Zhang, Hongzhong Jin

{"title":"Expanding the therapeutic horizons of spesolimab: a review of off-label applications for inflammatory skin diseases.","authors":"Hanlin Zhang, Jia Zhou, Keyun Tang, Xinyi Zhang, Hongzhong Jin","doi":"10.1080/09546634.2025.2460582","DOIUrl":"https://doi.org/10.1080/09546634.2025.2460582","url":null,"abstract":"Purpose: This review aims to outline the crucial role of IL-36 signaling in inflammatory skin diseases and summarize the therapeutic potential of spesolimab. Our goal is to provide insights into the off-label applications of spesolimab and future directions for its use in treating other challenging skin diseases.Materials and methods: We conducted a comprehensive literature search across PubMed, Embase, Web of Science, MEDLINE, Scopus, and the Cochrane Library to identify relevant studies. For RCTs, we additionally searched the ClinicalTrials.gov database.Results: In this review, we examine its off-label applications for conditions such as palmoplantar pustulosis, acrodermatitis continua of Hallopeau, hidradenitis suppurativa, pyoderma gangrenosum, and acute generalized exanthematous pustulosis. This review also explores the role of IL-36 in the pathophysiology of these disorders and discusses how spesolimab may address the limitations of current therapies for refractory cases. Randomized controlled trials and case reports are summarized to highlight the efficacy and tolerability of spesolimab across various inflammatory skin conditions. We highlight the challenges presented by the absence of standardized treatment guidelines and the need for larger clinical trials.Conclusions: This review underscores the potential of spesolimab to enhance treatment strategies for inflammatory skin diseases.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2460582"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic review, methodological appraisal, and recommendation mapping of clinical practice guidelines for managing patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-26 DOI: 10.1080/09546634.2025.2467751

Mohammed AlFada, Hend Alotaibi, Sahar Alsharif, Ahmad Hecham Alani, Andrea Andrade-Miranda, Camila Montesinos Guevara, Yaolong Chen, Ruobing Lei, Jorge Acosta-Reyes, Pamela Velásquez-Salazar, Ahmed El-Malky, Yasser S Amer

{"title":"Systematic review, methodological appraisal, and recommendation mapping of clinical practice guidelines for managing patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.","authors":"Mohammed AlFada, Hend Alotaibi, Sahar Alsharif, Ahmad Hecham Alani, Andrea Andrade-Miranda, Camila Montesinos Guevara, Yaolong Chen, Ruobing Lei, Jorge Acosta-Reyes, Pamela Velásquez-Salazar, Ahmed El-Malky, Yasser S Amer","doi":"10.1080/09546634.2025.2467751","DOIUrl":"https://doi.org/10.1080/09546634.2025.2467751","url":null,"abstract":"Purpose: The Appraisal of Guidelines for Research and Evaluation II Instrument (AGREE II) was developed to enhance the methodological rigor of clinical practice guidelines (CPGs), aiming to generate trustworthy recommendations for various clinical scenarios. Despite its importance, there exists a gap in the quality of CPGs pertaining to Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS-TEN). The aim of the study was to evaluate SJS-TEN CPGs to shed light on areas for enhancing SJS-TEN guidelines' quality.Materials and methods: A systematic review was conducted to identify SJS-TEN CPGs from January 2011 to December 2023 across bibliographic and guideline databases, as well as dermatology association websites. Four reviewers employed the AGREE II instrument to appraise the quality of eligible CPGs. Subsequently, AGREE II domain scores were calculated and their recommendations mapped.Results and conclusions: Seven eligible SJS-TEN CPGs reviewed, originating from Europe, North America, Asia, and an authorship Group. The highest AGREE II domain scores were observed in scope and purpose (mean: 63%, standard deviation [SD]: 23.195%) and clarity of presentation (mean: 70%, SD: 14.5%). Conversely, the lowest score was noted in the applicability domain (mean: 28%, SD: 17.44%). Only two guidelines by the British Association of Dermatologists (28.6%) met the 'recommend' level. Recommendations from all CPGs were compared in tabular form.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2467751"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A multicenter pilot study of the effectiveness and safety of a monopolar radiofrequency device for improving periorbital and facial fine wrinkles.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-03-11 DOI: 10.1080/09546634.2025.2469633

Hee Joo Yang, Sun Young Choi, Joon Min Jung, Yoon-Seo Jo, Hye Sung Han, Young In Lee, Ju Hee Lee, Chong Hyun Won

{"title":"A multicenter pilot study of the effectiveness and safety of a monopolar radiofrequency device for improving periorbital and facial fine wrinkles.","authors":"Hee Joo Yang, Sun Young Choi, Joon Min Jung, Yoon-Seo Jo, Hye Sung Han, Young In Lee, Ju Hee Lee, Chong Hyun Won","doi":"10.1080/09546634.2025.2469633","DOIUrl":"https://doi.org/10.1080/09546634.2025.2469633","url":null,"abstract":"Purpose: This study aimed to investigate the effectiveness and safety of a new monopolar radiofrequency device equipped with a 5 cm2 tip, against fine wrinkles around the eyes and cheeks.Materials and methods: This multicentered, prospective pilot study involved treating participants with mild-to-moderate wrinkles on both periorbital areas and cheeks using the monopolar radiofrequency device for one session. One and four months after treatment, wrinkle reduction, overall esthetic improvement, adverse events, and vital signs were evaluated.Results: The study involved 13 participants (age: 35-62 years) and on a five-point scale, periorbital wrinkles showed a significant reduction at 4 weeks (0.96 ± 0.65) and 16 weeks (1.04 ± 0.59). On a five-point scale, cheek wrinkles also decreased at weeks 4 and 16 (1.00 ± 0.55 and 1.12 ± 0.64, respectively). On a five-point scale (range: -1-3), overall global esthetic improvement was rated by the participants at weeks 4 and 16 to be 2.23 ± 0.80 and 2.31 ± 0.61, respectively. Adverse events were not observed during the follow-up.Conclusion: A single session using the new monopolar radiofrequency device equipped with a 5 cm2 tip safely and effectively improves mild-to-moderate periorbital and facial wrinkles.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2469633"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Whether the transient hair shedding phase exist after minoxidil treatment and does it predict treatment efficacy? A retrospective study in androgenetic alopecia patients.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-03-23 DOI: 10.1080/09546634.2025.2480739

Lingbo Bi, Haili Kan, Jing Wang, Yunbu Ding, Yuanbo Huang, Chaofan Wang, Yimei Du, Changpei Lu, Min Zhao, Weiling Sun, Tong Su, Weixin Fan

{"title":"Whether the transient hair shedding phase exist after minoxidil treatment and does it predict treatment efficacy? A retrospective study in androgenetic alopecia patients.","authors":"Lingbo Bi, Haili Kan, Jing Wang, Yunbu Ding, Yuanbo Huang, Chaofan Wang, Yimei Du, Changpei Lu, Min Zhao, Weiling Sun, Tong Su, Weixin Fan","doi":"10.1080/09546634.2025.2480739","DOIUrl":"https://doi.org/10.1080/09546634.2025.2480739","url":null,"abstract":"Purpose: Minoxidil is a routinely used drug in treating multiple hair disorders. This study aimed to investigate the facticity of the temporal increase in the hair shedding amount after topical use of minoxidil.Materials and methods: We selected 49 patients who used 2% or 5% minoxidil topically to treat androgenetic alopecia for 24 weeks. The amount of hair shedding was recorded every four weeks before and after the treatment. The BASP classification and trichoscopy test results were also recorded before and after the treatment. The relative amount of hair shedding (RAHS) was defined as the recorded number of hair shedding after normalization. The correlation between the maximum RAHS (MRAHS) and the sulfotransferase activity as well as the therapeutic effect was calculated.Results: A temporary increase in the amount of hair shedding was detected in the first 12 weeks. This increase has a longer duration in patients treated with 2% minoxidil compared to 5%. Its severity was correlated with the improvement of trichoscopy tests only in patients with 5% minoxidil but not in 2%. However, both patients in the 2% and 5% minoxidil groups had a significant association between the MRAHS and the improvement in BASP classification.Conclusion: The amount of hair shedding increases temporarily after the topical minoxidil use, the level of which is a potential treatment efficacy.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2480739"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Portuguese consensus on first line treatment of moderate-to-severe psoriasis with a non-TNF inhibitor therapy - a delphi methodology.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-01-27 DOI: 10.1080/09546634.2025.2453601

Tiago Torres, Sofia Magina, Maria João Paiva Lopes

{"title":"Portuguese consensus on first line treatment of moderate-to-severe psoriasis with a non-TNF inhibitor therapy - a delphi methodology.","authors":"Tiago Torres, Sofia Magina, Maria João Paiva Lopes","doi":"10.1080/09546634.2025.2453601","DOIUrl":"https://doi.org/10.1080/09546634.2025.2453601","url":null,"abstract":"Introduction: Psoriasis (PsO) is a common chronic, inflammatory, immune-mediated disease. In 2023, a 4.4% prevalence of PsO was reported in Portugal. Currently, Tumor Necrosis Factor inhibitors (TNFi) are the recommended first-line (1 L) biologic agents in Portugal given their lower cost. However, TNFi may not be suitable for several patients. In these patients, interleukin inhibitors (ILi) should be considered as they provide more effective outcomes and a better safety profile.Methods: Qualitative interviews with PsO experts were conducted to identify PsO biologic treatment needs, resulting in an online survey to explore clinical cases focused on subpopulations of PsO. A delphi study evaluated consensus on clinical criteria to initiate non-TNFi therapy in seven predefined subpopulations of patients.Results: This study highlights the benefit of starting non-TNFi therapy in all PsO predefined subpopulations. Patients with infection risk, mild heart failure and associated comorbidities, autoimmune diseases and family history of demyelinating disease consensually benefit from starting non-TNFi therapy in 1 L. Several risks associated with latent tuberculosis, advanced age and oncological disease were also evaluated.Conclusion: Given the existence of various risks associated with TNFi usage, this clinical perspective overview of Portuguese experts in PsO treatment emphasizes the need for a tailored therapeutic framework in the management of PsO.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2453601"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143054222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use magnified images to help define the boundaries of melanonychia in surgery.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-02 DOI: 10.1080/09546634.2025.2459153

Simin He, Siliang Xue

引用次数: 0

Effect of amniotic fluid on hair follicle growth. 羊水对毛囊生长的影响。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-01-19 DOI: 10.1080/09546634.2025.2451389

Gamze Tumentemur, Elif Ganime Aygun, Bulut Yurtsever, Didem Cakirsoy, Ercument Ovali

{"title":"Effect of amniotic fluid on hair follicle growth.","authors":"Gamze Tumentemur, Elif Ganime Aygun, Bulut Yurtsever, Didem Cakirsoy, Ercument Ovali","doi":"10.1080/09546634.2025.2451389","DOIUrl":"https://doi.org/10.1080/09546634.2025.2451389","url":null,"abstract":"Purpose: Human amniotic fluid stem cells (hAFSCs) have shown significant regenerative potential in treating hair loss, wound healing, and tissue repair. This study aims to evaluate the effects of human amniotic fluid (hAF) on hair follicle (HF) regeneration and immune system modulation.Materials and Methods: The hAF used was pooled, acellular, and gamma-irradiated to standardize its contents and enhance its stability. Both irradiated (FAFI) and non-irradiated (FAF) hAF were assessed for their efficacy and safety in promoting hair growth and modulating immune responses in a rat model of hair loss. The study examined HF regeneration, transition to the anagen phase, and macrophage polarization from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype.Results: Both FAF and FAFI treatments significantly increased HF density, with FAFI exhibiting enhanced effects. Histological analysis demonstrated improved HF regeneration, increased M2 macrophages, and reduced collagen fiber deposition in treated areas. Gamma irradiation likely improved the efficacy of FAFI by stabilizing active components and inhibiting protease activity.Conclusions: Irradiated hAF is a safe and effective therapeutic candidate for alopecia and HF growth disorders. These findings support further evaluation of hAF in clinical trials to validate its potential for hair regeneration therapies.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2451389"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-03-25 DOI: 10.1080/09546634.2025.2480744

Zelma C Chiesa Fuxench, Zhihong Lai, YuTzu Kuo, Haq Nawaz, Jonathan Cotliar

{"title":"Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial.","authors":"Zelma C Chiesa Fuxench, Zhihong Lai, YuTzu Kuo, Haq Nawaz, Jonathan Cotliar","doi":"10.1080/09546634.2025.2480744","DOIUrl":"https://doi.org/10.1080/09546634.2025.2480744","url":null,"abstract":"Purpose: Ruxolitinib cream was evaluated in patients with facial/neck atopic dermatitis (AD) in a decentralized, double-blind, randomized clinical trial (NCT05127421).Materials and methods: Patients aged 12-70 years with AD (Investigator's Global Assessment [IGA] score 2/3, ≤20% affected body surface area [face/neck, ≥0.5%]) were randomized 2:1 to twice-daily 1.5% ruxolitinib cream or vehicle for 4 weeks; thereafter, all patients applied as-needed ruxolitinib cream for 4 additional weeks. The primary endpoint was ≥75% improvement in head/neck Eczema Area and Severity Index (EASI-75) at Week 4 assessed by blinded central reader using photographs.Results: Among 77 randomized patients (median [range] age, 38.0 [17-66] y), 44.2% were Black. The mean (SD) baseline head/neck EASI was 1.2 (0.7). More patients who applied ruxolitinib cream vs vehicle achieved head/neck EASI-75 at Week 4 (37.0% vs 17.4%; p = 0.091). Improvements with ruxolitinib cream vs vehicle were observed for facial/neck IGA treatment success (IGA 0/1 with ≥2-point improvement from baseline) and Patient-Oriented Eczema Measure (overall and itch). Ruxolitinib cream was well tolerated, including on the face and neck. Application site reactions were infrequent (ruxolitinib cream, 1.9% [n = 1]; vehicle, 8.7% [n = 2]).Conclusions: Ruxolitinib cream improved signs and symptoms of facial/neck AD vs vehicle and was well tolerated.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2480744"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Abrocitinib alleviates the symptoms of Netherton syndrome and is well tolerated.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-03-30 DOI: 10.1080/09546634.2024.2447883

Jun-Ting Tang, Yu-Liang Qin, Wei-Jia Zhao, Ying Tu, Dong-Jie Sun

{"title":"Abrocitinib alleviates the symptoms of Netherton syndrome and is well tolerated.","authors":"Jun-Ting Tang, Yu-Liang Qin, Wei-Jia Zhao, Ying Tu, Dong-Jie Sun","doi":"10.1080/09546634.2024.2447883","DOIUrl":"https://doi.org/10.1080/09546634.2024.2447883","url":null,"abstract":"Purpose: To investigate the potential genetic basis of Netherton syndrome (NS) through first- and second-generation DNA sequencing techniques. Additionally, we evaluated the therapeutic efficacy of Abrocitinib in NS patients.Materials and methods: We conducted whole-exome sequencing analysis on a pedigree comprising one affected individual with NS. Subsequently, the identified patient was treated with Abrocitinib, and clinical improvements in cutaneous manifestations were systematically assessed.Results: Genetic analysis revealed that the patient harbored compound heterozygous mutations in the SPINK5 gene, including a missense mutation in exon 26 (c.2475G > T, p.Trp825Cys). Following six months of Abrocitinib therapy, the patient exhibited marked improvement in skin rash and overall disease severity.Conclusions: Our findings suggest that SPINK5 missense mutations may contribute to the pathogenesis of NS. Furthermore, Abrocitinib demonstrates promising therapeutic potential in the management of NS, warranting further investigation in larger clinical cohorts.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2447883"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0